1. Expanded access programs, compassionate drug use, and emergency use authorizations during the COVID-19 pandemic;Rizk;Drug Discovery Today,2021
2. Baricitinib, methotrexate, or combination in patients with rheumatoid arthritis and no or limited p1r00ior disease-modifying antirheumatic drug treatment;Fleischmann;Arthritis & Rheumatology,2017
3. British Pharmacopoeia Stationary Office, Medicines and Healthcare Products Regulatory Agency. 2022; London, Vol. II.
4. The United States Pharmacopoeia 43 Revision, NF 38. 2022; the United States Pharmacopoeia Convention Inc.
5. Development and validation of a stability indicating related substances of baricitinib by RP-HPLC and its degradation;Mohan;Int J Manag Hum,2019